ETERNA THERAPEUTICS INC (ERNA)
US1140822099 - Common Stock
ISRG Stock Alert: The FDA Is Giving Intuitive Surgical a Big Boost
Intuitive Surgical stock is on the rise Friday as investors in ISRG shares learn about FDA approval for the company's da Vinci 5.
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023
Eterna Therapeutics just reported results for the fourth quarter of 2023.
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
Eterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of Directors...
Eterna Therapeutics files to sell 18.2M shares for holders (NASDAQ:ERNA)
Eterna Therapeutics files prospectus for $25M mixed shelf offering, not an offer to sell securities.
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed...
Eterna Therapeutics names Sanjeev Luther as CEO (NASDAQ:ERNA)
Eterna Therapeutics names Sanjeev Luther as President and CEO.
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed...
Eterna Therapeutics launches convertible debt and warrant financing of up to $9.2M (ERNA)
Eterna Therapeutics secures $9.2 million through the sale of convertible promissory notes and warrants in a private placement.
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start of the trading week with a look at the biggest pre-market stock movers worth watching on Monday morning!
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed...
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications Novel...
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company...
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
CAMBRIDGE, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed...
Eterna Therapeutics Appoints Megan Yung as Chief Strategy Officer, General Counsel
CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company...
Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Approach is potentially first iPS cell-derived multi-cell-type therapeutic strategy designed to mimic how the human immune system naturally fights disease ...
Eterna Therapeutics to Deliver Eight Presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Eterna to present data on iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, nucleic-acid delivery, and targeted gene...
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics
Acquisition includes Exacis’ entire pipeline of engineered cell therapy programs for hematologic and solid tumors CAMBRIDGE, Mass., May 02, 2023 (GLOBE...
Eterna Therapeutics files for offering of 2.93M shares by holder (NASDAQ:ERNA)
Eterna Therapeutics (ERNA) has filed for an offering of 2.93M shares of its common stock, $0.005 par value per share, by selling stockholder, Lincoln Park Capital Fund.Pursuant to...
Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million
CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company...
Jeff Karp, Ph.D., Joins Eterna’s Scientific Advisory Board
Renowned scientist and serial entrepreneur Jeff Karp, Ph.D., brings deep research experience and industry knowledge that will help guide Eterna as it...
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
– Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell (iPSC)-derived therapies...
Lineage, Eterna team up to develop cell lines for neurological conditions (NYSE:LCTX)
Lineage Cell Therapeutics (LCTX) and Eterna Therapeutics (ERNA) signed an option and license agreement to develop novel beta 2 microglobulin (B2M)-deficient induced pluripotent stem...
Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a preclinical-stage biotechnology company...
Eterna Therapeutics chief medical officer to resign (NASDAQ:ERNA)
Roger Sidhu, chief medical officer at Eterna Therapeutics (ERNA), is resigning effective Jan. 31.
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...